Scholarlink

<p>IMiDs (immunomodulatory drugs from the thalidomide class) enhance hemoglobin F (HbF) production but are not yet approved for sickle cell disease (SCD). Here, we describe a case of severe SCD and multiple myeloma (MM) in which over 6&#xa0;years of treatment with IMiDs and hydroxyurea led to sustained remission of SCD.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A case of SCD controlled by IMiDs and hydroxyurea

  • 期刊论文

  • 发表日期：

    2025年12月27日

查看全文
  • Ashrei Bayewitz,
  • Sai Shalini Pillarisetty,
  • Fatemeh Moeini Nia

摘要

IMiDs (immunomodulatory drugs from the thalidomide class) enhance hemoglobin F (HbF) production but are not yet approved for sickle cell disease (SCD). Here, we describe a case of severe SCD and multiple myeloma (MM) in which over 6 years of treatment with IMiDs and hydroxyurea led to sustained remission of SCD.

Graphical Abstract